MC MEDIA NETWORK

#mood

Όλες οι Ειδήσεις

Advertisement

NIPD Genetics launches Rodinia infertility test

Advertisement

Sponsored by exness

Personalized insight for family planning

NIPD Genetics announces the launch of Rodinia, a new genetic test that screens for mutations associated with infertility in individuals and couples who have difficulty conceiving and maintaining a pregnancy.

Advertisement

Infertility is considered a major disorder of the reproductive system and affects approximately 1 in 6 couples worldwide. Rodinia identifies the underlying genetic cause of infertility and provides deep insight about reproductive potential and health. Early detection of mutations associated with infertility can improve prognosis and be pivotal to the choice and outcome of treatment.

Rodinia is available as a female or a male infertility panel. Each panel detects numerous infertility-causing genetic variants as well as whole, partial, or mosaic sex chromosome copy number changes. The female infertility panel screens for 55 genes and includes disorders like primary ovarian insufficiency, ovarian hyperstimulation syndrome and hypogonadotropic hypogonadism and copy number changes in the X chromosome. The male infertility panel screens for 40 genes, and includes disorders such as hypogonadotropic hypogonadism, like Kallmann syndrome, copy number changes in X and Y chromosomes and Y-chromosome microdeletions.  Rodinia also offers an add-on haemophilia and thrombosis panel that checks for 21 specific genetic variants, in a total of 16 genes, associated with recurrent pregnancy loss. Rodinia is built on NIPD Genetics’ novel and patented technology platform that has been thoroughly validated in several studies and is trusted for its accuracy and precision.

Rodinia is performed by a doctor through a non-invasive buccal swab. The sample is sent to NIPD Genetics’ central laboratories for analysis. Results are reported back to the healthcare provider within 2-4 weeks, allowing them to take informed and early decisions on the best clinical management.

Prof. Philippos Patsalis, Founder and CEO of NIPD Genetics, stated that “Rodinia provides invaluable clinical utility to healthcare professionals by helping them to take a personalized approach to family planning for each couple or individual. Rodinia can guide them in making informed decisions that raise the chances of achieving pregnancy”.

Rodinia can be beneficial for couples or individuals experiencing delay in conceiving; women with irregular or absent menstruation; men with low sperm count, irregular sperm form or movement; and individuals with external characteristics indicating a syndrome associated with sex development. Rodinia can also be beneficial for couples or individuals that will undergo assisted reproductive technology treatment, candidates for sperm or oocyte donation, and individuals with family history of infertility.

Ακολουθήστε την Cyprus Times στο Google news και μάθετε πρώτοι όλες τις ειδήσεις.

Δείτε όλες τις Ειδήσεις από την Κύπρο και τον κόσμο στη Cyprus Times

Advertisement

Trending

Advertisement

Ροή Ειδήσεων

Advertisement
Advertisement
Advertisement

Διαβάστε Επίσης

Advertisement
Advertisement

Best of Network